Gliosarcoma clinical trials
18 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
- Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
- A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
- Study of Pembrolizumab and M032 (NSC 733972)
- Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
- A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
- Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
- Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
- Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
- Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Gliosarcoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.